These innovative molecules represent a significant leap in the management of type 2 diabetes. Retatrutide, a dual GLP-1 and GIP receptor agonist, demonstrates promising efficacy in controlling blood glucose levels. https://jayaohxl072790.dm-blog.com/39233830/novel-glp-1-receptor-agonists-retatrutide-and-trizepatide